Creation of immune 'stealth' genes for gene therapy through fusion with the Gly-Ala repeat of EBNA-1

Gene Therapy

Volumn 10, Issue 24, 2003, Pages 2020-2028

  Ossevoort, M ^a   Visser, B M J ^a   van den Wollenberg, D J M ^a   van der Voort, E I H ^a   Offringa, R ^a   Melief, C J M ^a   Toes, R E M ^a   Hoeben, R C ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Epstein Barr virus; Immune evasion; Proteasome; Thymidine kinase; Viral vector

Indexed keywords

ADENOVIRUS VECTOR; ALANINE; BETA GALACTOSIDASE; EPSTEIN BARR VIRUS ANTIGEN; GLYCINE; LUCIFERASE; THYMIDINE KINASE;

ANTIGEN RECOGNITION; ARTICLE; CELL LINE; CLINICAL PROTOCOL; CONTROLLED STUDY; ENZYME ACTIVITY; GENE EXPRESSION REGULATION; GENE FUSION; GENE THERAPY; GENE TRANSFER; GENETIC LINKAGE; HERPES SIMPLEX VIRUS 1; IMMUNE RESPONSE; MOUSE; NONHUMAN; NUCLEOTIDE REPEAT; PRIORITY JOURNAL; PROTEIN DOMAIN; T LYMPHOCYTE; VIRAL GENE DELIVERY SYSTEM;

ADENOVIRIDAE; ANIMALS; ANTIGEN PRESENTATION; ARTIFICIAL GENE FUSION; BETA-GALACTOSIDASE; CYTOTOXICITY, IMMUNOLOGIC; DIPEPTIDES; EPSTEIN-BARR VIRUS NUCLEAR ANTIGENS; GENE THERAPY; GENETIC VECTORS; IMMUNE TOLERANCE; LAC OPERON; MICE; MICE, INBRED BALB C; T-LYMPHOCYTES, CYTOTOXIC; TRANSGENES;

ADENOVIRIDAE; DNA VIRUSES; ESCHERICHIA COLI; HUMAN HERPESVIRUS 1; HUMAN HERPESVIRUS 4; SIMPLEXVIRUS;

EID: 0242440881     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gt.3302098     Document Type: Article

References (59)

1. Christ M et al. Gene therapy with recombinant adenovirus vectors: evaluation of the host immune response. Immunol Lett 1997; 57: 19-25.
2. Geutskens SB et al. Recombinant adenoviral vectors have adjuvant activity and stimulate T cell responses against tumor cells. Gene Therapy 2000; 7: 1410-1416.
3. Michou AI et al. Adenovirus-mediated gene transfer: influence of transgene, mouse strain and type of immune response on persistence of transgene expression. Gene Therapy 1997; 4: 473-482.
4. Yang Y, Ertl HC, Wilson JM. MHC class I-restricted cytotoxic T lymphocytes to viral antigens destroy hepatocytes in mice infected with E1-deleted recombinant adenoviruses. Immunity 1994; 1: 433-442.
5. Sullivan NJ et al. Development of a preventive vaccine for Ebola virus infection in primates. Nature 2000; 408: 605-609.
6. Ulmer JB et al. Heterologous protection against influenza by injection of DNA encoding a viral protein. Science 1993; 259: 1745-1749.
7. Cordier L et al. Complete recovery of mice from a pre-established tumor by direct intratumoral delivery of an adenovirus vector harboring the murine IL-2 gene. Gene Therapy 1995; 2: 16-21.
8. Toes RE et al. Protective anti-tumor immunity induced by vaccination with recombinant adenoviruses encoding multiple tumor-associated cytotoxic T lymphocyte epitopes in a string-of-beads fashion. Proc Natl Acad Sci USA 1997; 94: 14660-14665.
9. Kay MA, Glorioso JC, Naldini L. Viral vectors for gene therapy: the art of turning infectious agents into vehicles of therapeutics. Nat Med 2001; 7: 33-40.
10. Molinier-Frenkel V et al. Immune response to recombinant adenovirus in humans: capsid components from viral input are targets for vector-specific cytotoxic T lymphocytes. J Virol 2000; 74: 7678-7682.
11. Abina MA et al. LacZ gene transfer into tumor cells abrogates tumorigenicity and protects mice against the development of further tumors. Gene Therapy 1996; 3: 212-216.
12. Cordier L et al. Muscle-specific promoters may be necessary for adeno-associated virus-mediated gene transfer in the treatment of muscular dystrophies. Hum Gene Ther 2001; 12: 205-215.
13. Jooss K et al. Transduction of dendritic cells by DNA viral vectors directs the immune response to transgene products in muscle fibers. J Virol 1998; 72: 4212-4223.
14. Juillard V et al. Long-term humoral and cellular immunity induced by a single immunization with replication-defective adenovirus recombinant vector. Eur J Immunol 1995; 25: 3467-3473.
15. Yang Y, Su Q, Wilson JM. Role of viral antigens in destructive cellular immune responses to adenovirus vector-transduced cells in mouse lungs. J Virol 1996; 70: 7209-7212.
16. Yang Y, Wilson JM. Clearance of adenovirus-infected hepatocytes by MHC class I-restricted CD4+CTLs in vivo. J Immunol 1995; 155: 2564-2570.
17. Ye X et al. Transient depletion of CD4 lymphocyte improves efficacy of repeated administration of recombinant adenovirus in the ornithine transcarbamylase deficient sparse fur mouse. Gene Therapy 2000; 7: 1761-1767.
18. Zsengeller ZK et al. Persistence of replication-deficient adenovirus-mediated gene transfer in lungs of immune-deficient (nu/nu) mice. Hum Gene Ther 1995; 6: 457-467.
19. Kolls JK et al. Use of transient CD4 lymphocyte depletion to prolong transgene expression of E1-deleted adenoviral vectors. Hum Gene Ther 1996; 7: 489-497.
20. Chirmule N et al. Repeated administration of adenoviral vectors in lungs of human CD4 transgenic mice treated with a nondepleting CD4 antibody. J Immunol 1999; 163: 448-455.
21. Yang Y et al. Cellular immunity to viral antigens limits E1-deleted adenoviruses for gene therapy. Proc Natl Acad Sci USA 1994; 91: 4407-4411.
22. Yang Y et al. Cellular and humoral immune responses to viral antigens create barriers to lung-directed gene therapy with recombinant adenoviruses. J Virol 1995; 69: 2004-2015.
23. Yang Y et al. Immunology of gene therapy with adenoviral vectors in mouse skeletal muscle. Hum Mol Genet 1996; 5: 1703-1712.
24. Latta-Mahieu M et al. Gene transfer of a chimeric trans-activator is immunogenic and results in short-lived transgene expression. Hum Gene Ther 2002; 13: 1611-1620.
25. Thomis DC et al. A Fas-based suicide switch in human T cells for the treatment of graft-versus-host disease. Blood 2001; 97: 1249-1257.
26. Kay MA et al. Long-term hepatic adenovirus-mediated gene expression in mice following CTLA4Ig administration. Nat Genet 1995; 11: 191-197.
27. Yang Y et al. Immune responses to viral antigens versus transgene product in the elimination of recombinant adenovirus-infected hepatocytes in vivo. Gene Therapy 1996; 3: 137-144.
28. Yang Y et al. Transient subversion of CD40 ligand function diminishes immune responses to adenovirus vectors in mouse liver and lung tissues. J Virol 1996; 70: 6370-6377.
29. Wiertz EJ, Mukherjee S, Ploegh HL. Viruses use stealth technology to escape from the host immune system. Mol Med Today 1997; 3: 116-123.
30. Ploegh HL. Viral strategies of immune evasion. Science 1998; 280: 248-253.
31. Khanna R et al. Localization of Epstein-Barr virus cytotoxic T cell epitopes using recombinant vaccinia: implications for vaccine development. J Exp Med 1992; 176: 169-176.
32. Khanna R et al. Isolation of cytotoxic T lymphocytes from healthy seropositive individuals specific for peptide epitopes from Epstein-Barr virus nuclear antigen 1: implications for viral persistence and tumor surveillance. Virology 1995; 214: 633-637.
33. Munz C et al. Human CD4(+) T lymphocytes consistently respond to the latent Epstein-Barr virus nuclear antigen EBNA1. J Exp Med 2000; 191: 1649-1660.
34. Blake N et al. Human CD8+T cell responses to EBV EBNA1: HLA class I presentation of the (Gly-Ala)-containing protein requires exogenous processing. Immunity 1997; 7: 791-802.
35. Blake N et al. The importance of exogenous antigen in priming the human CD8+T cell response: lessons from the EBV nuclear antigen EBNA1. J Immunol 2000; 165: 7078-7087.
36. Rickinson AB, Moss DJ. Human cytotoxic T lymphocyte responses to Epstein-Barr virus infection. Annu Rev Immunol 1997; 15: 405-431.
37. Levitskaya J et al. Inhibition of antigen processing by the internal repeat region of the Epstein-Barr virus nuclear antigen-1. Nature 1995; 375: 685-688.
38. Levitskaya J et al. Inhibition of ubiquitin/proteasome-dependent protein degradation by the Gly-Ala repeat domain of the Epstein-Barr virus nuclear antigen 1. Proc Natl Acad Sci USA 1997; 94: 12616-12621.
39. Gavin MA et al. Alkali hydrolysis of recombinant proteins allows for the rapid identification of class I MHC-restricted CTL epitopes. J Immunol 1993; 151: 3971-3980.
40. Toes RE et al. Protective antitumor immunity induced by immunization with completely allogeneic tumor cells. Cancer Res 1996; 56: 3782-3787.
41. Sharipo A et al. A minimal glycine-alanine repeat prevents the interaction of ubiquitinated I kappaB alpha with the proteasome: a new mechanism for selective inhibition of proteolysis. Nat Med 1998; 4: 939-944.
42. Sharipo A et al. cis-Inhibition of proteasomal degradation by viral repeats: impact of length and amino acid composition. FEBS Lett 2001; 499: 137-142.
43. Dantuma NP et al. Inhibition of proteasomal degradation by the gly-Ala repeat of Epstein-Barr virus is influenced by the length of the repeat and the strength of the degradation signal. Proc Natl Acad Sci USA 2000; 97: 8381-8385.
44. Tellam J et al. Targeting of EBNA1 for rapid intracellular degradation overrides the inhibitory effects of the Gly-Ala repeat domain and restores CD8+T cell recognition. J Biol Chem 2001; 276: 33353-33360.
45. Heessen S et al. Functional p53 chimeras containing the Epstein-Barr virus Gly-Ala repeat are protected from Mdm2- and HPV-E6-induced proteolysis. Proc Natl Acad Sci USA 2002; 99: 1532-1537.
46. Bevan MJ. Cross-priming for a secondary cytotoxic response to minor H antigens with H-2 congenic cells which do not cross-react in the cytotoxic assay. J Exp Med 1976; 143: 1283-1288.
47. Sigal LJ et al. Cytotoxic T-cell immunity to virus-infected non-haematopoietic cells requires presentation of exogenous antigen. Nature 1999; 398: 77-80.
48. Benihoud K, Yeh P, Perricaudet M. Adenovirus vectors for gene delivery. Curr Opin Biotechnol 1999; 10: 440-447.
49. Price J, Turner D, Cepko C. Lineage analysis in the vertebrate nervous system by retrovirus-mediated gene transfer. Proc Natl Acad Sci USA 1987; 84: 156-160.
50. He TC et al. A simplified system for generating recombinant adenoviruses. Proc Natl Acad Sci USA 1998; 95: 2509-2514.
51. Fallaux FJ et al. Characterization of 911: a new helper cell line for the titration and propagation of early region 1-deleted adenoviral vectors. Hum Gene Ther 1996; 7: 215-222.
52. Fallaux FJ et al. New helper cells and matched early region 1-deleted adenovirus vectors prevent generation of replication-competent adenoviruses. Hum Gene Ther 1998; 9: 1909-1917.
53. Pietersen AM et al. Specific tumor-cell killing with adenovirus vectors containing the apoptin gene. Gene Therapy 1999; 6: 882-892.
54. de Roos WK et al. Isolated-organ perfusion for local gene delivery: efficient adenovirus-mediated gene transfer into the liver. Gene Therapy 1997; 4: 55-62.
55. Hoeben RC et al. Inactivation of the Moloney murine leukemia virus long terminal repeat in murine fibroblast cell lines is associated with methylation and dependent on its chromosomal position. J Virol 1991; 65: 904-912.
56. van der Eb MM et al. Severe hepatic dysfunction after adenovirus-mediated transfer of the herpes simplex virus thymidine kinase gene and ganciclovir administration. Gene Therapy 1998; 5: 451-458.
57. Hoerr I et al. In vivo application of RNA leads to induction of specific cytotoxic T lymphocytes and antibodies. Eur J Immunol 2000; 30: 1-7.
58. Toes RE et al. An adenovirus type 5 early region 1B-encoded CTL epitope-mediating tumor eradication by CTL clones is down-modulated by an activated ras oncogene. J Immunol 1995; 154: 3396-3405.
59. Chalmers D et al. Elimination of the truncated message from the herpes simplex virus thymidine kinase suicide gene. Mol Ther 2001; 4: 146-148.